

Supplementary Table 1. Comparison of estimated annualized bleeding rates for any, spontaneous, and traumatic bleeds, in patients receiving prophylaxis with rFIXFc versus N9-GP, after matching baseline variables of patients in the B-LONG study¹ with those in and PARADIGM 2.²

Rates with 95% confidence intervals are shown in the table.

Scenario	MAIC model [†]	Any bleeding			Spontaneous bleeding			Traumatic bleeding		
		ABR N9-GP*	ABR rFIXFc	IRR rFIXFc vs N9-GP	ABR N9-GP*	ABR rFIXFc	IRR rFIXFc vs N9-GP	ABR N9-GP*	ABR rFIXFc	IRR rFIXFc vs N9-GP
Weekly prophylaxis	Naïve		3.11 (2.42–4.01)	1.24 (0.67–2.31)		1.64 (1.18–2.28)	1.34 (0.50–3.61)		1.27 (0.85–1.90)	0.98 (0.50–1.91)
	Adjusted		2.55 (1.99–3.27)	1.02 (0.55–1.89)		1.29 (0.93–1.80)	1.06 (0.39–2.85)		1.15 (0.78–1.68)	0.89 (0.46–1.71)
Individualized prophylaxis	Naïve	2.51	2.35 (1.58–3.51)	0.94 (0.47–1.88)	1.22	1.40 (0.86–2.28)	1.15 (0.40–3.29)	1.29	0.74 (0.36–1.52)	0.57 (0.23–1.40)
	Adjusted	(1.42–4.43)	2.70 (1.84–3.97)	1.08 (0.54–2.14)	(0.48–3.10)	1.47 (0.90–2.41)	1.21 (0.42–3.47)	(0.76–2.19)	1.08 (0.58–2.04)	0.84 (0.37–1.91)
Pooled arms	Naïve		2.85 (2.30–3.52)	1.13 (0.62–2.08)		1.56 (1.19–2.04)	1.28 (0.48–3.37)		1.08 (0.78–1.51)	0.84 (0.45–1.57)
	Adjusted		2.59 (2.10–3.19)	1.03 (0.56–1.89)		1.34 (1.02–1.76)	1.10 (0.42–2.91)		1.13 (0.82–1.56)	0.88 (0.47–1.63)

*Efficacy data for patients assigned to N9-GP 40 IU/kg once weekly treatment group; [†]Naïve values show unadjusted data; modeling used data adjusted for age, weight, prior prophylaxis, White race, Asian ethnicity and the presence of target joints at baseline.

ABR, annualized bleeding rate; IRR, incidence rate ratio; MAIC, matching adjusted indirect comparison; N9-GP, nonacog beta pegol; rFIXFc, recombinant factor IX Fc fusion protein.

References

1. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. *N Engl J Med*. 2013;369(24):2313–23.
2. Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. *Blood*. 2014;124(26):3880–6.